Wednesday, June 03, 2015 8:45:55 AM
You forget to mention at the lowest dose of 0.015mg/kg it was 7/(58%) 
.
Look, Irilumab may not be the mildest cancer drug but it is within the
range of tolerable. Currently it is in the effiKIR trial which will have
result in Q2 2016. It has been reviewed by the DSMB 4 times, the last time
resulting in cancelling one of the study arm which was a buying opportunity
to me.
If there was any safety issue, the DSMB would have stopped the study.
The poster was available a while back. Knowing it would spook investors,
I dumped all my shares on 5/28 when it was at 17. I probably buy it back
at sometime in the future.
. Look, Irilumab may not be the mildest cancer drug but it is within the
range of tolerable. Currently it is in the effiKIR trial which will have
result in Q2 2016. It has been reviewed by the DSMB 4 times, the last time
resulting in cancelling one of the study arm which was a buying opportunity
to me.
If there was any safety issue, the DSMB would have stopped the study.
The poster was available a while back. Knowing it would spook investors,
I dumped all my shares on 5/28 when it was at 17. I probably buy it back
at sometime in the future.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
